蔚藍生物：子公司擬2.03億元投建年產1000噸功能性食用益生菌系列產品技術改造項目
格隆匯2月10日丨蔚藍生物(603739.SH)公佈，公司全資子公司山東蔚藍生物科技有限公司(“山東蔚藍”)擬在山東蔚藍現有廠區內投資建設年產1000噸功能性食用益生菌系列產品技術改造項目，該項目總投資約2.03億元，其中建設投資為約1.87億元，流動資金1506萬元，項目建設所需資金全部由山東蔚藍自行籌集。該項目已在惠民縣工業和信息化局備案。
該項目地址位於山東蔚藍廠區內。建成後將實現年產1000噸功能性食用益生菌系列產品的生產能力。項目總佔地面積19980平方米，建築面積17320平方米，主要建設內容包括：研發中心，發酵車間，後處理車間，智能化包裝車間、倉庫等。
近年來，益生菌這一概念愈發深入人心，其功能也逐漸被人們所熟知。隨着消費升級的推進，益生菌產業迎來了快速發展的黃金時期，同時也為我國食品工業的產業轉型升級發揮着重要作用。益生菌產品在全世界範圍的銷售與增長一直保持着良好的勢頭。益生菌產業下游應用鏈非常廣，橫跨功能性食品、保健品、日化用品、藥品等多個行業。目前國內的產業規模和擴張還遠未能滿足日益增長的市場需求。
公司已在動植物用益生菌的研發和生產上積累了多年的實際經驗。同時，公司在2018年通過引進國內外高端人才(在杜邦-丹尼斯克和丹麥科漢森做過菌種研發的人才)，重點投資，組建了營養與健康技術中心，專攻食品益生菌的研發。目前在人用益生菌研發上已掌握了一定的關鍵性先進技術，並擁有了幾株有自主知識產權的功能性菌株，更多的新菌株也正在開發中，為接下來的生產做好了一定準備。
項目建成後，山東蔚藍將通過高密度發酵、凍幹保護等高科技工藝技術，主要生產高濃縮的活性益生菌菌粉。依照市場需求，活性菌粉可進一步加工成益生菌食品、固體飲料、藥品等的終端形式，還可用於化粧品。具有發酵風味的功能性菌株也會用於生產益生菌發酵液、發酵食品(如酸奶、功能性發酵乳)等。另外，年產1,000噸功能性食用益生菌的生產能力在國內同類企業中位於前列，除使用蔚藍生物自有的菌株生產相應產品外，山東蔚藍也將擁有強大的代工生產能力。項目的實施將進一步豐富公司的產品結構，促進公司的持續發展，符合公司的發展戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
